busulfan and abt-199
busulfan has been researched along with abt-199 in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC | 1 |
| Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM | 1 |
| Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B | 1 |
| Cao, Y; Chen, X; Feng, S; Gao, H; Han, M; Jiang, E; Lu, N; Pang, A; Shen, B; Wang, M; Wei, J; Yang, D; Zhai, W; Zhang, H; Zhang, R; Zheng, X; Zheng, Y | 1 |
Trials
1 trial(s) available for busulfan and abt-199
| Article | Year |
|---|---|
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine | 2021 |
Other Studies
3 other study(ies) available for busulfan and abt-199
| Article | Year |
|---|---|
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides | 2020 |
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine | 2022 |
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
Topics: Aged; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Transplantation Conditioning | 2023 |